Amgen Inc. (NASDAQ:AMGN) Shares Sold by DGS Capital Management LLC

DGS Capital Management LLC decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 39.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,502 shares of the medical research company’s stock after selling 997 shares during the period. DGS Capital Management LLC’s holdings in Amgen were worth $392,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Capital Performance Advisors LLP acquired a new stake in Amgen during the 3rd quarter worth approximately $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen during the third quarter worth approximately $29,000. Hershey Financial Advisers LLC acquired a new stake in shares of Amgen during the second quarter worth $30,000. Matrix Trust Co purchased a new position in Amgen in the 3rd quarter valued at $36,000. Finally, Livelsberger Financial Advisory acquired a new position in Amgen in the 3rd quarter valued at $56,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Amgen stock opened at $275.42 on Friday. The stock has a market capitalization of $148.05 billion, a P/E ratio of 35.27, a P/E/G ratio of 2.78 and a beta of 0.56. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The firm’s 50-day moving average is $271.39 and its two-hundred day moving average is $305.99.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Amgen’s revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the business earned $4.96 earnings per share. Equities analysts predict that Amgen Inc. will post 19.56 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.46%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is presently 115.24%.

Analysts Set New Price Targets

Several research firms have recently commented on AMGN. Redburn Partners reduced their target price on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft lowered their price objective on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Wolfe Research assumed coverage on Amgen in a research note on Friday, November 15th. They set a “peer perform” rating for the company. Leerink Partners reduced their price target on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Finally, StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Amgen has an average rating of “Hold” and an average price target of $314.65.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.